Jeff Baldetti, MBA

Jeff Baldetti, MBA, is director of biosimilars for Cardinal Health.

Opinion: How Will Semglee Interchangeable Insulin Affect Access and Affordability?

July 29, 2021

The approval of Biocon Biologics and Viatris' insulin glargine product as an interchangeable biosimilar will be a test of whether such designations can make a difference in patient access, Jeff Baldetti, MBA, of Cardinal Health explains.